Is the pneumovax vaccine still recommended for blood type O,as mentioned in ER4YT? I did not find it recommended in LR4YT. Regards!

In ER4YT I recommended the Pneumococcal vaccine ('Pneumovax') as a potential way to increase the levels of anti-A antibodies. This is desirable as many common cancers are 'A-like'. Since type O's and B's can manufacture anti-A, this provided a simple, safe and effective way to 'retrain' their immune systems into thinking that any such cancer bet treated like an improper blood transfusion.

Unfortunately, the element in the Pneumovax that induced anti-A antibodies turned out to be an 'impurity' and further refining of the vaccine was performed to eliminate it.

However, in re-evaulating the work of Georg Springer for my book Live Right 4 Your Type, it became evident that the typhoid vaccine conveyed even more beneficial elements. In addition it is employable by type As and ABs.

Georg F. Springer, MD, spent over 20 years harnessing the potential of the immune system to combat cancer. Although his treatments were outside of the mainstream, he was anything but (coming from a very traditional medical and research background). Originally, a pioneer in work with blood group antigens, Springer dedicated his life and his unique expertise to breast cancer after his wife died from this disease. His work eventually led him to the development of what is known as "Springer's Vaccine" and his reported five and ten-year survival rates for stage II, III, and IV breast cancer with this novel T (Thomson-Friedenreich) and Tn antigen therapy are nothing short of amazing when compared against standard treatments.

Springer's work capitalized on this difference between healthy and cancerous cells and his knowledge of the immune system to create a vaccine, which specifically stimulated the immune system to fight cells with these stumps (T and Tn antigens). His vaccine consisted of three parts: 1) chemically degraded O-group blood cells (providing T and Tn antigens), 2) the Salmonella typhii vaccine or typhoid vaccine (which contains T and Tn antigens), and 3) calcium phosphate (he believed the T and Tn antigens could stick to this).

His protocol entailed giving his vaccine to patients subcutaneously (under the skin), initially at 6-week intervals, eventually extending the gap to 12 weeks. For people receiving chemotherapy, he would wait 3 to 4 weeks after cessation of the last round of chemotherapy prior to beginning his treatment. In the case of radiation, he would wait 1 to 3 months after the last dose of radiation prior to initiating treatment. He recommended that his patients receive this vaccine "ad infinatum".

Many malignant cells (such as those found in breast and stomach cancer) develop a tumor marker called the Thomsen-Friedenreich (T) antigen. This antigen is suppressed in normal healthy cells, much like a rock is covered over by water at high tide. T antigen only becomes 'unsuppressed' as a cell moves towards malignancy, much like the covered rock in our example becomes uncovered as the tide moves out. It is so rare to find the T antigen in healthy tissue, that most people actually have and antibody to it. T antigen is both 'M' and 'A' like. Springer's work and several other independent studies have shown that the injectable Typhoid vaccine (not the oral form) can increase the levels of circulating anti-T.

Typhoid vaccine is commonly used when peopel travel to endemic areas of Typhoid infestation, such as Africa or South East Asia. It is a safe vaccine with an superior safety track record. While this vaccine cannot be expected to produce the outcomes Springer appeared to be achieving, it is one of the only options that I am aware of for possibly promoting increased amounts of T and Tn antibodies. As such it offers a potential to work in an area that is ignored in most cancer protocols. At its worst it will offer you a degree of protection against typhoid. This vaccine is safe for all blood types.

For more information consult the typhoid vaccine entry in the Immunology Knowledge Base.



1. Springer GF, Desai PR, Tegtmeyer H, Carlstedt SC, Scanlon EF. T/Tn antigen vaccine is effective and safe in preventing recurrence of advanced human breast carcinoma. Cancer Biother. 1994 Spring;9(1):7-15.

2. Springer GF. T and Tn pancarcinoma markers: autoantigenic adhesion molecules in pathogenesis, prebiopsy carcinoma-detection, and long-term breast carcinoma immunotherapy. Crit Rev Oncog. 1995;6(1):57-85. Review